A5023553051- Liver Disease Diagnosis and Treatment
- Liver Disease and Transplantation
- Hepatocellular Carcinoma Treatment and Prognosis
- Liver physiology and pathology
- Hepatitis C virus research
- Liver Diseases and Immunity
- Pediatric Hepatobiliary Diseases and Treatments
- Angiogenesis and VEGF in Cancer
- Pancreatitis Pathology and Treatment
- Cancer, Hypoxia, and Metabolism
- Alcohol Consumption and Health Effects
- Diet, Metabolism, and Disease
- Pancreatic and Hepatic Oncology Research
- Organ Transplantation Techniques and Outcomes
- Gallbladder and Bile Duct Disorders
- Hepatitis B Virus Studies
- Cancer, Lipids, and Metabolism
- Hormonal Regulation and Hypertension
- Virus-based gene therapy research
- Drug-Induced Hepatotoxicity and Protection
- Cancer Mechanisms and Therapy
- Protease and Inhibitor Mechanisms
- Drug Transport and Resistance Mechanisms
- Complement system in diseases
- Eicosanoids and Hypertension Pharmacology
Nara Medical University
2016-2025
Nara City Hospital
2025
Nara Medical University Hospital
2005-2024
Takeda (United States)
2021-2022
Nagoya University
2022
Honda (Japan)
2022
Keio University
2022
Weatherford College
2021
Murata (United States)
2021
The Japanese Society of Gastroenterological Surgery
2021
Recent basic and clinical studies have shown that the programmed death ligand (PD-L)/PD-1 pathway has a significant role in tumour immunity, its blockade therapeutic potential against several human cancers. We hypothesized anti-angiogeneic treatment might augment efficacy of PD-1 blockade. To this end, we evaluated combining vascular endothelial growth factor receptor 2 (VEGFR2) murine cancer model using Colon-26 adenocarcinoma. Interestingly, simultaneous with anti-PD-1 anti-VEGFR2...
We previously reported that the incidence of hepatocellular carcinoma (HCC) with non-viral etiologies increased rapidly between 1991 and 2010 in Japan.
Sodium‐glucose cotransporter 2 inhibitors (SGLT2‐Is) comprise a new class of antidiabetic agents that inhibit glucose reabsorption in the renal proximal tubules. Although recent report demonstrated potential ability SGLT2‐Is to attenuate cancer growth SGLT2‐expressing cells, little is known about effects on hepatocellular carcinoma (HCC). Here, we investigate anti‐cancer properties SGLT2‐I, canagliflozin, against human liver cells. SGTL2 mRNA and protein expression were detected Huh7 HepG2...
Abstract The first edition of the clinical practice guidelines for liver cirrhosis was published in 2010, and second 2015 by Japanese Society Gastroenterology (JSGE). revised third recently 2020. This version has become a joint guideline JSGE Hepatology (JSH). In addition to questions (CQs), background (BQs) are new items basic knowledge, future research (FRQs) newly added clinically important items. Concerning treatment cirrhosis, findings have been reported over past 5 years since edition....
A nationwide survey in 2018 showed decreasing involvement of viral hepatitis and increasing nonviral liver diseases the etiology cirrhosis (LC) Japan. An updated was undertaken 2023.
The renin-angiotensin system (RAS) is frequently activated in patients with chronic liver diseases. Angiotensin-II (AT-II) has been suggested to play an important role fibrogenesis. It induces hepatic stellate cell (HSC) proliferation and up-regulates the transforming growth factor beta(1) (TGF-beta(1)) expression via AT-II type 1 receptor (AT(1)-R) vitro. aim of present study was examine vivo effect candesartan (CA), a clinically used AT(1)-R blocker (ARB), perindopril (PE),...
<b>Background:</b> It has been shown that expression of the potent angiogenic factor, vascular endothelial growth factor (VEGF), and its receptors, flt-1 (VEGFR-1) KDR/Flk-1 (VEGFR-2), increased during development liver fibrosis. <b>Aims:</b> To elucidate in vivo role interaction between VEGF receptors fibrogenesis. <b>Methods:</b> A model CCl<sub>4</sub> induced hepatic fibrosis was used to assess VEGFR-1 VEGFR-2 by means specific neutralising monoclonal antibodies (R-1mAb R-2mAb,...
Tissue inhibitor of metalloproteinases-1 (TIMP-1) has been shown to be increased in liver fibrosis development both murine experimental models and human samples. However, the direct role TIMP-1 during not defined. To address this issue, we developed transgenic mice overexpressing (hTIMP-1) under control albumin promoter/ enhancer. A model CCl(4)-induced hepatic was used assess extent (TIMP-Tg) hybrid (Cont) mice. Without any treatment, overexpression itself did induce fibrosis. There were no...
It has been suggested that the tissue inhibitor of metalloproteinases-1 (TIMP-1) is involved in spontaneous resolution liver fibrosis. The aim this study was to investigate whether TIMP-1 altered fibrosis conjunction with matrix metalloproteinases (MMP) inhibition and hepatic stellate cell (HSC) activation. livers liver-targeted transgenic (TIMP-Tg) control hybrid (Cont) mice were harvested at 0, 3, 7, 28 days following recovery from CCl 4 -induced extent resolution, MMP expression,...
Increasing evidence has indicated that perturbation of cyclins is one the major factors leading to cancer. The aim this study was not only investigate various cell cycle-related kinase activities in hepatocellular carcinoma (HCC), but also analyze difference activity levels between hepatitis C virus (HCV)-induced HCC and HCV-induced cirrhosis. protein D1, E, A, H, cyclin dependent 1 (Cdk1), Cdk2, Cdk4, Cdk6, Cdk7 surrounding nontumorous cirrhosis were determined by Western blot. enzymatic...
Little is known about the effect of hepatitis C virus (HCV) infection on gut microbiota and relationship between alteration chronic (CHC) progression. We performed a comparative study composition CHC patients healthy individuals.Fecal samples from 166 were compared with those 23 individuals; community was analyzed using 16S ribosomal RNA gene sequencing. diagnosed persistently normal serum alanine aminotransferase without evidence liver cirrhosis (LC) (PNALT, n = 18), (CH, 84), LC (n 40),...
Summary Decreased plasma ADAMTS13 activity (ADAMTS13:AC) results in the accumulation of unusually large von Willebrand factor multimer (UL-VWFM) and formation platelet thrombi. It remains controversial whether or not ADAMTS13:AC decreases patients with liver cirrhosis (LC), its relationship to clinical features has been fully investigated. We measured related parameters 33 chronic hepatitis (CH) 109 LC. decreased increasing severity disease (controls means 100%, CH 87%, Child A-LC 79%, B-LC...
Background & AimsThere is still a risk for hepatocellular carcinoma (HCC) development after eradication of hepatitis C virus (HCV) infection with antiviral agents. We investigated genetic factors associated the HCC in patients sustained virologic response (SVR) to treatment chronic HCV infection.MethodsWe obtained genomic DNA from 457 Japan SVR interferon-based 2007 through 2015. conducted genome-wide association study (GWAS), followed by replication analysis 79 candidate single nucleotide...
The once-daily, all oral, RBV-free, pangenotypic direct-acting anti-viral regimen consisting of co-formulated NS3/4A protease inhibitor glecaprevir and NS5A pibrentasvir (G/P), demonstrated high rates sustained virologic response (SVR) in phase 2 3 studies outside Japan. CERTAIN-1 is a 3, open-label, multicenter study assessing the safety efficacy G/P (300/120 mg) once daily Japanese patients with chronic HCV GT1 infection. Patients without cirrhosis received 8 weeks or 12...
In Japan, bezafibrate (BF) is a second-line agent for primary biliary cholangitis (PBC) that refractory to ursodeoxycholic acid (UDCA) treatment. From retrospective cohort (n = 873) from the Japan PBC Study Group, we enrolled 118 patients who had received UDCA monotherapy at least 1 year followed by combination therapy with UDCA+BF year. GLOBE and UK-PBC scores after (i.e., immediately before therapy) were compared those of therapy. The real outcomes estimated Kaplan-Meier analysis predicted...
To determine the efficacy of rifaximin for hepatic encephalopathy (HE) with linkage gut microbiome in decompensated cirrhotic patients.Twenty patients (12 men and 8 women; median age, 66.8 years; range, 46-81 years) cirrhosis (Child-pugh score > 7) underwent cognitive neuropsychological testing, endotoxin analysis, fecal assessment at baseline after 4 wk treatment 400 mg thrice a day. HE was determined by serum ammonia level number connection test (NCT)-A. Changes whole blood activity (EA)...